Camosunate

Active Ingredients & Dual Mechanism of Action

1. Artesunate: A water-soluble artemisinin derivative that acts rapidly against the blood-stage malaria parasites. It generates reactive oxygen radicals that disrupt the cellular membranes of parasites, resulting in fast symptom relief and rapid clearance of parasite load.
2. Amodiaquine: A 4-aminoquinoline antimalarial that acts more slowly but stays in the body longer. It inhibits the parasite’s ability to detoxify heme into non-toxic hemozoin, causing toxic heme buildup that destroys the parasite cell.

Available Formulations & Strengths

• Paediatric Powder (0 to 11 months): Sachets containing 25 mg Artesunate / 75 mg Amodiaquine base.
• Children Powder (1 to 6 years): Sachets containing 50 mg Artesunate / 150 mg Amodiaquine base.
• Junior Tablets (7 to 13 years): Co-packaged blister packs containing white Artesunate tablets (100 mg) and yellow Amodiaquine tablets (300 mg).
• Adult Tablets (14 years and above): Co-packaged blister packs containing Artesunate tablets (100 mg) and Amodiaquine tablets (300 mg).

Clinical Indications

• Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria.
• Note: Camosunate is not used for malaria prevention (prophylaxis) and is not suitable as primary treatment for severe or cerebral malaria requiring intravenous therapy.

Key Pharmacokinetics

• Absorption: Artesunate is rapidly absorbed and converted to its active metabolite (dihydroartemisinin). Amodiaquine is quickly absorbed from the GI tract and converted in the liver to its long-acting metabolite, desethylamodiaquine.
• Half-Life: Artesunate has a short half-life ($\sim 45\text{ minutes}$) for rapid action. Amodiaquine and its active metabolite have a long half-life, providing sustained antimalarial activity over weeks.

Administration Guidelines

• Duration: Standard treatment duration is 3 consecutive days.
• Powder Sachets: Dissolve granules/powder in a small amount of clean water before taking.
• Timing: Follow the age-appropriate schedule as prescribed by a healthcare provider.
• Vomiting: If vomiting occurs within 30 minutes of taking a dose, repeat the full dose. If vomiting persists, switch to injectable antimalarial therapy for severe malaria.

Safety Profile & Considerations

• Common Side Effects: Dizziness, fatigue, nausea, vomiting, abdominal cramps, loss of appetite, and itching/pruritus.
• Contraindications:
  • Known hypersensitivity to artesunate, amodiaquine, or related compounds.
  • History of severe liver damage or blood disorders (such as agranulocytosis) during previous amodiaquine treatment.
  • Retinopathy (in cases of repeated treatment).
• Pregnancy & Lactation: Avoid use during the first trimester of pregnancy unless advised by a physician under high-risk clinical judgment. Use in later trimesters requires strict medical supervision.
• Key Interactions: Caution when used alongside hepatotoxic drugs or other agents that alter liver enzyme activity.

Note: Camosunate is a prescription antimalarial. Completing the full 3-day course is necessary to prevent treatment failure and parasite resistance, even if symptoms resolve quickly.